ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
119.662,38
0,08%
S&P 500
5.431,60
-0,04%
US Dollar vs BRL
5,37634
0,48%
Bitcoin
66.008,82
-0,94%
Brent Oil
82,475
0,43%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Neurocrine Biosciences Inc (NBIX)

  7. Neurocrine Biosciences Inc (NBIX) Notícias

NBIX

Neurocrine Biosciences (NBIX)

Neurocrine Biosciences Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:NBIX
DataHoraFonteTítuloCódigoCompanhia
04/06/202417:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
03/06/202409:01PR Newswire (US)Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024NASDAQ:NBIXNeurocrine Biosciences Inc
03/06/202408:35PR Newswire (US)Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of MedicineNASDAQ:NBIXNeurocrine Biosciences Inc
03/06/202408:30PR Newswire (US)Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of MedicineNASDAQ:NBIXNeurocrine Biosciences Inc
29/05/202417:53Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
29/05/202417:01PR Newswire (US)Neurocrine Biosciences to Participate at Investor Conferences in JuneNASDAQ:NBIXNeurocrine Biosciences Inc
28/05/202417:14PR Newswire (US)Neurocrine Biosciences Announces CEO Succession PlanNASDAQ:NBIXNeurocrine Biosciences Inc
28/05/202409:30PR Newswire (US)Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024NASDAQ:NBIXNeurocrine Biosciences Inc
23/05/202417:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBIXNeurocrine Biosciences Inc
21/05/202417:05PR Newswire (US)Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) CapsulesNASDAQ:NBIXNeurocrine Biosciences Inc
14/05/202409:30PR Newswire (US)Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024NASDAQ:NBIXNeurocrine Biosciences Inc
09/05/202410:45PR Newswire (US)Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024NASDAQ:NBIXNeurocrine Biosciences Inc
09/05/202409:30PR Newswire (US)Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy AdultsNASDAQ:NBIXNeurocrine Biosciences Inc
08/05/202409:30PR Newswire (US)Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy AdultsNASDAQ:NBIXNeurocrine Biosciences Inc
07/05/202417:15PR Newswire (US)Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care ConferenceNASDAQ:NBIXNeurocrine Biosciences Inc
07/05/202409:30PR Newswire (US)Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024NASDAQ:NBIXNeurocrine Biosciences Inc
06/05/202409:30PR Newswire (US)Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and MonitoringNASDAQ:NBIXNeurocrine Biosciences Inc
03/05/202414:15PR Newswire (US)Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024NASDAQ:NBIXNeurocrine Biosciences Inc
01/05/202408:00PR Newswire (US)Neurocrine Biosciences Reports First Quarter 2024 Financial ResultsNASDAQ:NBIXNeurocrine Biosciences Inc
30/04/202418:12PR Newswire (US)Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) CapsulesNASDAQ:NBIXNeurocrine Biosciences Inc
24/04/202409:30PR Newswire (US)Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia CommunityNASDAQ:NBIXNeurocrine Biosciences Inc
23/04/202408:00PR Newswire (US)Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive DisorderNASDAQ:NBIXNeurocrine Biosciences Inc
16/04/202417:01GlobeNewswire Inc.Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF PeptidesNASDAQ:NBIXNeurocrine Biosciences Inc
10/04/202417:01PR Newswire (US)Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial ResultsNASDAQ:NBIXNeurocrine Biosciences Inc
03/04/202409:30PR Newswire (US)Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive DisorderNASDAQ:NBIXNeurocrine Biosciences Inc
28/03/202409:30PR Newswire (US)Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy AdultsNASDAQ:NBIXNeurocrine Biosciences Inc
11/03/202417:01PR Newswire (US)Neurocrine Biosciences to Participate at Virtual Investor Conferences in MarchNASDAQ:NBIXNeurocrine Biosciences Inc
27/02/202418:01PR Newswire (US)Neurocrine Biosciences to Participate at Investor Conferences in MarchNASDAQ:NBIXNeurocrine Biosciences Inc
09/02/202419:29Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NBIXNeurocrine Biosciences Inc
07/02/202409:00PR Newswire (US)Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024NASDAQ:NBIXNeurocrine Biosciences Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:NBIX

Seu Histórico Recente

BIT
ENV
Enervit
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados